Evidence map›Paper›PMID 25704985›Full record

ArticleJournal of magnetic resonance imaging : JMRI2015

Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.

Hyunki Kim, Yolanda E Hartman, Guihua Zhai, Thomas K Chung, Melissa L Korb, Timothy M Beasley, Tong Zhou, Eben L Rosenthal

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitations.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hyunki KimDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Yolanda E HartmanDepartment of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Guihua ZhaiDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Thomas K ChungDepartment of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID http://orcid.org/0000-0001-6148-1184
Melissa L KorbDepartment of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Timothy M BeasleyDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Tong ZhouDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Eben L RosenthalComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.
University of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
CD147 as a Novel Target in Head and Neck CancerR01CA142637 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROSENTHAL, EBEN L. · 2010 to 2014
$1.3M
NCI NIH HHS 2P30CA013148NCI NIH HHS 5R01CA142637-03NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA142637
6 · The paper itself

Abstract

purposeTo assess the early therapeutic effects of anti-EMMPRIN (extracellular matrix metalloprotease inducer) antibody with/without cisplatin or X-ray radiation in head and neck cancer mouse models using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). MATERIALS AND

methodsMice bearing SCC1 (or OSC19) tumor xenografts were treated with anti-EMMPRIN antibody, radiation, cisplatin, or anti-EMMPRIN antibody plus cisplatin (or radiation) for a week (n = 4-5 per group). DCE-MRI was carried out on a 9.4T small animal MR scanner on days 0, 3, and 7, and K(trans) values were averaged in a 0.5-mm-thick peripheral tumor region. Ki67 and CD31 staining were implemented for all tumors after imaging.

resultsThe K(trans) changes of SCC1 and OSC19 tumors treated with anti-EMMPRIN antibody for 3 days were -18 ± 8% and 4 ± 7%, respectively, which were significantly lower than those of control groups (39 ± 5% and 45 ± 7%; P = 0.0025 and 0.0220, respectively). When cisplatin was added, those were -42 ± 9% and -44 ± 9%, respectively, and with radiation, -45 ± 9% and -27 ± 10%, respectively, which were also significantly lower than those of control groups (P < 0.0001 for all four comparisons). In the eight groups untreated (served as control) or treated with anti-EMMPRIN antibody with/without cisplatin or radiation, the mean K(trans) change for 3 days was significantly correlated with the mean tumor volume change for 7 days (r = 0.74, P = 0.0346), Ki67-expressing cell density (r = 0.96, P = 0.0001), and CD31 density (r = 0.84, P = 0.0084).

conclusionDCE-MRI might be utilized to assess the early therapeutic effects of anti-EMMPRIN antibody with/without chemotherapy or radiotherapy in head and neck cancer.

Indexed as

AnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBasiginCell Line, TumorChemoradiotherapyCisplatinContrast MediaDrug MonitoringEarly Detection of CancerFemaleHead and Neck NeoplasmsHumansMagnetic Resonance ImagingMiceMice, NudeAntibodies, MonoclonalBasiginCisplatinContrast Mediaanti-EMMPRIN antibodycisplatinDCE-MRIhead and neck cancerradiotherapy

Identifiers

PMID25704985
PMCPMC4545484
OpenAlexW1909379535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.